•The goal of this strategic partnership is to develop ground-breaking drugs for the treatment of debilitating genetic dermatological conditions.
• Tyris’ expertise in novel non-viral gene therapy technology is synergistic with Almirall’s leading expertise in medical dermatology and commitment to deliver breakthrough medicines to patients.
Almirall, S.A. (BME:ALM), a global biopharmaceutical company based in Barcelona, and Tyris Therapeutics, a next generation gene therapy company founded by Columbus Venture Partners, have announced a strategic partnership today to tackle orphan dermatological conditions using non-viral gene therapies.
By combining Tyris’s innovative non-viral based gene therapy technology and Almirall’s leading expertise in medical dermatology, the companies aim to develop next-generation gene therapies with transformational potential for the treatment for rare genetic dermatology diseases.
The two partners will collaborate closely via their core expertise. Tyris will be responsible for generating clinical lead candidates and progress them to clinical development.
Tyris would receive upfront and research milestone payments along with research funding and Almirall will have exclusive options to acquire gene therapy products and progress them through clinical development to commercialization. The economic terms of this collaboration have not been disclosed.
This new partnership demonstrates Almirall’s commitment to deliver breakthrough medicines to patients suffering from debilitating rare genetic dermatological diseases.
“We are thrilled to be joining forces with Columbus VP, one of the most experienced investors in the field of gene therapy.»
This strategic partnership facilitates the development of novel treatments options with the potential to make a significant difference to patients’ lives,” said Thomas Huber, Research Director at Almirall.
Tyris’ non-viral DNA-based technology has the potential to provide new avenues for the treatment of genetic diseases beyond the current viral-based gene therapy. The technology aims to deliver genes without size restrictions to specific tissues with the option for re-administration.
Unlike for viral-based gene therapy, this technology may be applicable for all patients, as no preexisting immunity or development of immune response against the vector is expected.
In addition, Tyris’ technology only requires the DNA sequence necessary for the therapeutic effect without carrying along any additional unwanted elements.
Damia Tormo, General Partner of Columbus VP and CEO of Tyris, stated,
“we are delighted to enter into this partnership and leverage Almirall’ s expertise in dermatology to accelerate the development of the most effective gene therapy solutions for many patients with dermatological genetic diseases currently without treatment.”
Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient’s needs through science to improve their lives.
Our Noble Purpose is at the core of our work:
“Transform the patients’ world by helping them realize their hopes and dreams for a healthy life.”
We invest in differentiated and groundbreaking medical dermatology products to bring our innovative solutions to patients in need.
The company, founded in 1943 and headquartered in Barcelona, is publically traded on the Spanish Stock Exchange and is a member of the IBEX 35 (ticker: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of patients.
Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2019 were 908.4 million euros.
For more information, please visit almirall.com
Founded in 2020, and fully owned by Columbus Venture Partners (columbusvp.com), Tyris Therapeutics SL is a privately held, fully integrated non-viral DNA-based gene therapy company dedicated to developing life-saving medicines.
Tyris’ DNA-based medicines platform includes proprietary technology to
i) produce linear closed DNA, just containing the sequence of interest, and
ii) novel non-viral vectors which have no limitation in cargo capacity and enables re-administration of any gene therapy treatment; thus, overcoming current challenges in viral gene therapy, achieving more efficient and safer therapeutics for any genetic disease.
Its pipeline covers a diverse preclinical portfolio initially focused on dermatological indications as well as on renal, hematological and pulmonary therapeutic indications.
In addition, Tyris is also exploring new horizons from a DNA-based perspective (eg vaccines, CAR-Ts or MAbs). Headquarters and main R&D laboratories are located in Valencia (Spain).
Almirall Media contact:
Phone: (+34) 93 93 545 0861
Tyris Media Contact:
Phone: (+34) 91 057 1655
Almirall Media contact:
Phone: (+34) 659 614 173
Almirall Investors’ relations contact:
Pablo Divasson del Fraile
Tel.: (+34) 932 913 087